Leuprolide

"Leuprolide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.

Descriptor ID	D016729
MeSH Number(s)	D06.472.699.327.740.320.400 D12.644.400.400.740.320.400 D12.644.456.460.480 D12.644.548.365.740.320.400 D12.776.631.650.405.740.320.400
Concept/Terms	Leuprolide Leuprolide Leuprorelin Enantone Enantone Leuprolide Acetate Leuprolide Acetate Acetate, Leuprolide Leuprolide Monoacetate Leuprolide Monoacetate Monoacetate, Leuprolide Leuprolide, (L-Leu)-Isomer Leuprolide, (L-Leu)-Isomer Lupron Lupron TAP-144 TAP-144 TAP 144 TAP144 A-43818 A-43818 A 43818 A43818 Leuprolide, (DL-Leu)-Isomer Leuprolide, (DL-Leu)-Isomer

Below are MeSH descriptors whose meaning is more general than "Leuprolide".

Chemicals and Drugs [D]
Hormones, Hormone Substitutes, and Hormone Antagonists [D06]
Hormones [D06.472]
Peptide Hormones [D06.472.699]
Hypothalamic Hormones [D06.472.699.327]
Pituitary Hormone-Releasing Hormones [D06.472.699.327.740]
Gonadotropin-Releasing Hormone [D06.472.699.327.740.320]
Leuprolide [D06.472.699.327.740.320.400]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Neuropeptides [D12.644.400]
Hypothalamic Hormones [D12.644.400.400]
Pituitary Hormone-Releasing Hormones [D12.644.400.400.740]
Gonadotropin-Releasing Hormone [D12.644.400.400.740.320]
Leuprolide [D12.644.400.400.740.320.400]
Oligopeptides [D12.644.456]
Gonadotropin-Releasing Hormone [D12.644.456.460]
Leuprolide [D12.644.456.460.480]
Peptide Hormones [D12.644.548]
Hypothalamic Hormones [D12.644.548.365]
Pituitary Hormone-Releasing Hormones [D12.644.548.365.740]
Gonadotropin-Releasing Hormone [D12.644.548.365.740.320]
Leuprolide [D12.644.548.365.740.320.400]
Proteins [D12.776]
Nerve Tissue Proteins [D12.776.631]
Neuropeptides [D12.776.631.650]
Hypothalamic Hormones [D12.776.631.650.405]
Pituitary Hormone-Releasing Hormones [D12.776.631.650.405.740]
Gonadotropin-Releasing Hormone [D12.776.631.650.405.740.320]
Leuprolide [D12.776.631.650.405.740.320.400]

Below are MeSH descriptors whose meaning is related to "Leuprolide".

Below are MeSH descriptors whose meaning is more specific than "Leuprolide".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Leuprolide" by people in this website by year, and whether "Leuprolide" was a major or minor topic of these publications.

Bar chart showing 64 publications over 28 distinct years, with a maximum of 6 publications in 2009 and 2019 and 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	2	0	2
1997	2	1	3
1998	1	1	2
1999	0	1	1
2000	1	0	1
2001	1	0	1
2002	1	0	1
2004	1	0	1
2005	1	0	1
2006	2	0	2
2007	1	1	2
2008	0	1	1
2009	5	1	6
2010	2	0	2
2011	1	0	1
2012	1	0	1
2013	0	1	1
2014	3	2	5
2015	1	0	1
2016	2	1	3
2018	2	0	2
2019	5	1	6
2020	3	0	3
2021	0	1	1
2022	1	1	2
2023	5	1	6
2024	2	2	4
2025	0	2	2

Below are the most recent publications written about "Leuprolide" by people in Profiles.

Freedland SJ, Mulhall JP, Gleave M, De Giorgi U, Saad F, Rannikko A, Ivanova JI, Nasr AF, Reisman AL, Ganguli A, Kral P, Turnbull J, Shore N. Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study. Eur Urol. 2025 05; 87(5):507-511.

View in: PubMed
Prebay ZJ, Fu D, Hochberg AR, Chung PH. Androgen deprivation therapy does not increase rates for reintervention, complication, or infection in primary penile implant or artificial urinary sphincter surgery: a retrospective cohort study from the TriNetX network. Int J Impot Res. 2025 Nov; 37(11):896-901.

View in: PubMed
Shore ND, Morgans AK, Tutrone RF. Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer. Future Oncol. 2024 Dec; 20(39):3179-3182.

View in: PubMed
Spratt DE, George DJ, Shore ND, Cookson MS, Saltzstein DR, Tutrone R, Bossi A, Brown BA, Lu S, Fallick M, Hanson S, Tombal BF. Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer. JAMA Oncol. 2024 05 01; 10(5):594-602.

View in: PubMed
Klein K, Klein KO, Miller BS, Mauras N. Unstimulated Luteinizing Hormone for Assessment of Suppression during Treatment of Central Precocious Puberty with 6-Month Subcutaneous Leuprolide Acetate: Correlations with Clinical Response. Horm Res Paediatr. 2025; 98(5):514-523.

View in: PubMed
Klein KO, Vargas Trujillo M, Dragnic S, Van Komen S, Li M, Lee PA. Timing of onset of menses after GnRH agonist treatment for central precocious puberty. J Pediatr Endocrinol Metab. 2024 May 27; 37(5):451-461.

View in: PubMed
Tutrone R, Saad F, George DJ, Tombal B, Bailen JL, Cookson MS, Saltzstein DR, Hanson S, Brown B, Lu S, Fallick M, Shore ND. Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Eur Urol Oncol. 2024 Aug; 7(4):906-913.

View in: PubMed
Freedland SJ, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Tutrone RF, Venugopal B, Woo HH, Ramirez-Backhaus M, Supiot S, Lantz A, Ganguli A, Ivanova J, Kral P, Huang SP, Saad F, Shore ND. Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer. NEJM Evid. 2023 12; 2(12):EVIDoa2300251.

View in: PubMed
Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Tarazi J, Sridharan S, Sugg J, Tang Y, Tutrone RF, Venugopal B, Villers A, Woo HH, Zohren F, Shore ND. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med. 2023 10 19; 389(16):1453-1465.

View in: PubMed
Tombal B, Collins S, Morgans AK, Hunsche E, Brown B, Zhu E, Bossi A, Shore N. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Eur Urol. 2023 12; 84(6):579-587.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement